pRetroX-Tet-Off Advanced

Retroviral vector to be used in conjunction with a Tet-responsive vector for doxycycline-repressible expression of a gene.

Sequence Author: Clontech (TaKaRa)

|Download SnapGene Viewer
No matches
SspI (7807) ScaI (7483) PvuI (7373) AlwNI (6526) SfiI (5816) BmtI (4892) NheI (4888) EcoRV (4746) BsgI (4655) PaeR7I - PspXI - XhoI (4605) RsrII (4291) CMV enhancer AscI (542) PshAI (676) BstEII (1252) Bpu10I (1455) BglII (1576) SbfI (2230) NotI (2243) AgeI (2250) BsiWI (2262) PacI (2273) BamHI (2278) XcmI (2292) NruI (2567) MfeI (2804) FseI (2911) EcoRI (3037) PaqCI (3399) PflMI (3513) BmgBI (3603) BstXI (3646) pRetroX-Tet-Off Advanced 8152 bp
SspI  (7807)
1 site
A A T A T T T T A T A A
ScaI  (7483)
1 site
A G T A C T T C A T G A
PvuI  (7373)
1 site
C G A T C G G C T A G C
AlwNI  (6526)
1 site
C A G N N N C T G G T C N N N G A C

Sticky ends from different AlwNI sites may not be compatible.
SfiI  (5816)
1 site
G G C C N N N N N G G C C C C G G N N N N N C C G G

Efficient cleavage requires at least two copies of the SfiI recognition sequence.
Sticky ends from different SfiI sites may not be compatible.
BmtI  (4892)
1 site
G C T A G C C G A T C G
NheI  (4888)
1 site
G C T A G C C G A T C G
EcoRV  (4746)
1 site
G A T A T C C T A T A G

EcoRV is reportedly more prone than its isoschizomer Eco32I to delete a base after cleavage.
BsgI  (4655)
1 site
G T G C A G ( N ) 14 N N C A C G T C ( N ) 14

Efficient cleavage requires at least two copies of the BsgI recognition sequence.
Sticky ends from different BsgI sites may not be compatible.
For full activity, add fresh S-adenosylmethionine (SAM).
PaeR7I  (4605)
1 site
C T C G A G G A G C T C

PaeR7I does not recognize the sequence CTCTCGAG.
PspXI  (4605)
1 site
V C T C G A G B B G A G C T C V
XhoI  (4605)
1 site
C T C G A G G A G C T C
RsrII  (4291)
1 site
C G G W C C G G C C W G G C

Efficient cleavage requires at least two copies of the RsrII recognition sequence.
Sticky ends from different RsrII sites may not be compatible.
For full activity, add fresh DTT.
AscI  (542)
1 site
G G C G C G C C C C G C G C G G
PshAI  (676)
1 site
G A C N N N N G T C C T G N N N N C A G

PshAI quickly loses activity at 37°C, but can be used at 25°C for long incubations.
BstEII  (1252)
1 site
G G T N A C C C C A N T G G

Sticky ends from different BstEII sites may not be compatible.
BstEII is typically used at 60°C, but is 50% active at 37°C.
Bpu10I  (1455)
1 site
C C T N A G C G G A N T C G

Cleavage may be enhanced when more than one copy of the Bpu10I recognition sequence is present.
This recognition sequence is asymmetric, so ligating sticky ends generated by Bpu10I will not always regenerate a Bpu10I site.
Sticky ends from different Bpu10I sites may not be compatible.
BglII  (1576)
1 site
A G A T C T T C T A G A
SbfI  (2230)
1 site
C C T G C A G G G G A C G T C C
NotI  (2243)
1 site
G C G G C C G C C G C C G G C G
AgeI  (2250)
1 site
A C C G G T T G G C C A
BsiWI  (2262)
1 site
C G T A C G G C A T G C

BsiWI is typically used at 55°C, but is 50% active at 37°C.
PacI  (2273)
1 site
T T A A T T A A A A T T A A T T
BamHI  (2278)
1 site
G G A T C C C C T A G G

After cleavage, BamHI-HF® (but not the original BamHI) can remain bound to DNA and alter its electrophoretic mobility.
XcmI  (2292)
1 site
C C A N N N N N N N N N T G G G G T N N N N N N N N N A C C

The 1-base overhangs produced by XcmI may be hard to ligate.
Sticky ends from different XcmI sites may not be compatible.
NruI  (2567)
1 site
T C G C G A A G C G C T
MfeI  (2804)
1 site
C A A T T G G T T A A C
FseI  (2911)
1 site
G G C C G G C C C C G G C C G G

FseI gradually loses activity when stored at -20°C.
EcoRI  (3037)
1 site
G A A T T C C T T A A G
PaqCI  (3399)
1 site
C A C C T G C ( N ) 4 G T G G A C G ( N ) 4 ( N ) 4

Efficient cleavage requires at least two copies of the PaqCI recognition sequence.
Sticky ends from different PaqCI sites may not be compatible.
Cleavage can be improved with PaqCI Activator.
PflMI  (3513)
1 site
C C A N N N N N T G G G G T N N N N N A C C

Sticky ends from different PflMI sites may not be compatible.
BmgBI  (3603)
1 site
C A C G T C G T G C A G

This recognition sequence is asymmetric, so ligating blunt ends generated by BmgBI will not always regenerate a BmgBI site.
BstXI  (3646)
1 site
C C A N N N N N N T G G G G T N N N N N N A C C

Sticky ends from different BstXI sites may not be compatible.
AmpR
6930 .. 7790  =  861 bp
286 amino acids  =  31.5 kDa
2 segments
   Segment 2:  
   6930 .. 7721  =  792 bp
   263 amino acids  =  28.9 kDa
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and related antibiotics
AmpR
6930 .. 7790  =  861 bp
286 amino acids  =  31.5 kDa
2 segments
   Segment 1:  signal sequence  
   7722 .. 7790  =  69 bp
   23 amino acids  =  2.6 kDa
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and related antibiotics
AmpR
6930 .. 7790  =  861 bp
286 amino acids  =  31.5 kDa
2 segments
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and related antibiotics
NeoR/KanR
3647 .. 4441  =  795 bp
264 amino acids  =  29.0 kDa
Product: aminoglycoside phosphotransferase from Tn5
confers resistance to neomycin, kanamycin, and G418 (Geneticin)
NeoR/KanR
3647 .. 4441  =  795 bp
264 amino acids  =  29.0 kDa
Product: aminoglycoside phosphotransferase from Tn5
confers resistance to neomycin, kanamycin, and G418 (Geneticin)
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 1:  TetR  
   2287 .. 2904  =  618 bp
   206 amino acids  =  23.3 kDa
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 2:  
   2905 .. 2910  =  6 bp
   2 amino acids  =  172.2 Da
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 3:  VP16 minimal transcriptional activation domain  
   2911 .. 2946  =  36 bp
   12 amino acids  =  1.4 kDa
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 4:  
   2947 .. 2949  =  3 bp
   1 amino acid  =  115.1 Da
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 5:  VP16 minimal transcriptional activation domain  
   2950 .. 2985  =  36 bp
   12 amino acids  =  1.4 kDa
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 6:  
   2986 .. 2988  =  3 bp
   1 amino acid  =  115.1 Da
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 7:  VP16 minimal transcriptional activation domain  
   2989 .. 3024  =  36 bp
   12 amino acids  =  1.3 kDa
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
   Segment 8:  
   3025 .. 3033  =  9 bp
   2 amino acids  =  172.2 Da
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
tTA-Advanced
2287 .. 3033  =  747 bp
248 amino acids  =  27.7 kDa
8 segments
Product: improved tetracycline-controlled transactivator
binds to a Tet-responsive element in the absence but not the presence of doxycycline
ori
6171 .. 6759  =  589 bp
high-copy-number ColE1/pMB1/pBR322/pUC origin of replication
ori
6171 .. 6759  =  589 bp
high-copy-number ColE1/pMB1/pBR322/pUC origin of replication
IRES
3060 .. 3633  =  574 bp
internal ribosome entry site (IRES) of the encephalomyocarditis virus (EMCV)
IRES
3060 .. 3633  =  574 bp
internal ribosome entry site (IRES) of the encephalomyocarditis virus (EMCV)
3' LTR (ΔU3)
4858 .. 5283  =  426 bp
self-inactivating 3' long terminal repeat (LTR) from Moloney murine leukemia virus
3' LTR (ΔU3)
4858 .. 5283  =  426 bp
self-inactivating 3' long terminal repeat (LTR) from Moloney murine leukemia virus
gag (truncated)
1151 .. 1567  =  417 bp
truncated MMLV gag gene lacking the start codon
gag (truncated)
1151 .. 1567  =  417 bp
truncated MMLV gag gene lacking the start codon
CMV enhancer
8081 .. 308  =  380 bp
human cytomegalovirus immediate early enhancer
CMV enhancer
8081 .. 308  =  380 bp
human cytomegalovirus immediate early enhancer
SV40 promoter
5549 .. 5878  =  330 bp
SV40 enhancer and early promoter
SV40 promoter
5549 .. 5878  =  330 bp
SV40 enhancer and early promoter
CMV enhancer
1604 .. 1907  =  304 bp
human cytomegalovirus immediate early enhancer
CMV enhancer
1604 .. 1907  =  304 bp
human cytomegalovirus immediate early enhancer
CMV promoter
309 .. 512  =  204 bp
human cytomegalovirus (CMV) immediate early promoter
CMV promoter
309 .. 512  =  204 bp
human cytomegalovirus (CMV) immediate early promoter
CMV promoter
1908 .. 2111  =  204 bp
human cytomegalovirus (CMV) immediate early promoter
CMV promoter
1908 .. 2111  =  204 bp
human cytomegalovirus (CMV) immediate early promoter
MMLV Ψ
751 .. 950  =  200 bp
packaging signal of Moloney murine leukemia virus (MMLV)
MMLV Ψ
751 .. 950  =  200 bp
packaging signal of Moloney murine leukemia virus (MMLV)
5' LTR (truncated)
513 .. 688  =  176 bp
truncated long terminal repeat from Moloney murine sarcoma virus
5' LTR (truncated)
513 .. 688  =  176 bp
truncated long terminal repeat from Moloney murine sarcoma virus
AmpR promoter
7791 .. 7895  =  105 bp
AmpR promoter
7791 .. 7895  =  105 bp
SV40 ori
5729 .. 5864  =  136 bp
SV40 origin of replication
SV40 ori
5729 .. 5864  =  136 bp
SV40 origin of replication
ORF:  2287 .. 3033  =  747 bp
ORF:  248 amino acids  =  27.7 kDa
ORF:  7060 .. 7326  =  267 bp
ORF:  88 amino acids  =  9.2 kDa
ORF:  2444 .. 2746  =  303 bp
ORF:  100 amino acids  =  11.2 kDa
ORF:  3647 .. 4441  =  795 bp
ORF:  264 amino acids  =  29.0 kDa
ORF:  3543 .. 3818  =  276 bp
ORF:  91 amino acids  =  10.3 kDa
ORF:  3819 .. 4205  =  387 bp
ORF:  128 amino acids  =  14.6 kDa
ORF:  3956 .. 4210  =  255 bp
ORF:  84 amino acids  =  9.6 kDa
ORF:  838 .. 1098  =  261 bp
ORF:  86 amino acids  =  9.5 kDa
ORF:  2560 .. 2823  =  264 bp
ORF:  87 amino acids  =  9.8 kDa
ORF:  5107 .. 5397  =  291 bp
ORF:  96 amino acids  =  10.5 kDa
ORF:  6930 .. 7790  =  861 bp
ORF:  286 amino acids  =  31.5 kDa
Click here to try SnapGene

Download pRetroX-Tet-Off Advanced.dna file

SnapGene

SnapGene is the easiest way to plan, visualize and document your everyday molecular biology procedures

  • Fast accurate construct design for all major molecular cloning techniques
  • Validate sequenced constructs using powerful alignment tools
  • Customize plasmid maps with flexible annotation and visualization controls
  • Automatically generate a rich graphical history of every edit and procedure

SnapGene Viewer

SnapGene Viewer is free software that allows molecular biologists to create, browse, and share richly annotated sequence files.

  • Gain unparalleled visibility of your plasmids, DNA and protein sequences
  • Annotate features on your plasmids using the curated feature database
  • Store, search, and share your sequences, files and maps

Individual Sequences & Maps

The maps, notes, and annotations in the zip file on this page are copyrighted material. This material may be used without restriction by academic, nonprofit, and governmental entities, except that the source must be cited as ’’www.snapgene.com/resources’’. Commercial entities must contact GSL Biotech LLC for permission and terms of use.

Discover the most user-friendly molecular biology experience.